NASDAQ : IMVT

Immunovant, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 29.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.12B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Details

NameImmunovant, Inc.
SectorHealthcare
IndustryBiotechnology
Employees315
Founded2018
CeoEric Venker
CountryUnited States
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
IsinUS45258J1025
Cusip45258J102
Cik1764013
Sic2836

Key executives

NameTitle
Dr. Eric Venker M.D., Pharm.D.Chief Executive Officer and Director
Dr. Frank M. Torti M.B.A., M.D.Executive Chairperson of the Board
Tiago M. Girao CPAChief Financial Officer
Melanie Gloria B.S.N.Chief Operating Officer
Dr. Jay S. Stout M.S., Ph.D.Chief Technology Officer
Christopher A. Van Tuyl Esq., J.D.Chief Legal Officer and Corporate Secretary
Christine BlodgettSenior Vice President of Human Resources
Becky MerlinaSenior Vice President and Global Head of Quality
Yan Zheng M.S., Ph.D.Senior Vice President of Biostatistics, Programming and Data Management
Sheetal Patel M.B.A., M.D., M.S.Senior Vice President of Clinical Development

Contact

Address1000 Park Forty Plaza, Suite 210, Durham, North Carolina 27713, United States
Phone917 410 3120
Websitehttps://immunovant.com